• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化疗期间及尸检时血浆和组织中的邻,对'-滴滴滴(米托坦)水平。

O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.

作者信息

von Slooten H, van Seters A P, Smeenk D, Moolenaar A J

出版信息

Cancer Chemother Pharmacol. 1982;9(2):85-8. doi: 10.1007/BF00265384.

DOI:10.1007/BF00265384
PMID:7172409
Abstract

The distribution of o,p'-DDD in various body compartments of patients being treated for metastatic adrenocortical carcinoma was studied. A highly significant semilogarithmic relationship was found between plasma and adipose tissue concentrations during therapy and between plasma and brain at autopsy. A linear relationship was found at autopsy between concentrations in adipose tissue and those in various other tissues, such as tumour and brain. The semilogarithmic relationship can be explained by the assumption of two plasma pools for o,p'-DDD, one with low affinity and high capacity and one with high affinity and low capacity. Plasma concentrations must be carefully monitored to obtain an impression of the tumour concentration and to detect impending central nervous system intoxication.

摘要

对接受转移性肾上腺皮质癌治疗的患者体内各身体腔室中邻对滴滴滴(o,p'-DDD)的分布进行了研究。在治疗期间,血浆与脂肪组织浓度之间以及尸检时血浆与脑之间发现了高度显著的半对数关系。尸检时发现脂肪组织与其他各种组织(如肿瘤和脑)中的浓度之间呈线性关系。这种半对数关系可以通过假设o,p'-DDD存在两个血浆池来解释,一个具有低亲和力和高容量,另一个具有高亲和力和低容量。必须仔细监测血浆浓度,以了解肿瘤浓度情况并检测即将发生的中枢神经系统中毒。

相似文献

1
O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.化疗期间及尸检时血浆和组织中的邻,对'-滴滴滴(米托坦)水平。
Cancer Chemother Pharmacol. 1982;9(2):85-8. doi: 10.1007/BF00265384.
2
[Metabolism of o,p'-DDD (mitotane) in human and animals. Actual notions and practical deductions (author's transl)].[人及动物体内邻对滴滴滴(米托坦)的代谢。当前观点与实际推论(作者译)]
Ann Endocrinol (Paris). 1977;38(1):13-25.
3
Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.肾上腺皮质溶解化合物3-甲基磺酰基-DDE和邻,对'-滴滴滴(米托坦)在小型猪体内的药代动力学
Cancer Chemother Pharmacol. 2008 Feb;61(2):267-74. doi: 10.1007/s00280-007-0468-x. Epub 2007 Apr 12.
4
Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.血浆米托坦及其代谢物水平测定在肾上腺癌患者中的临床作用:长期随访结果
J Exp Ther Oncol. 2005;5(2):125-32.
5
Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.低剂量米托坦(邻,对'-滴滴滴)及其代谢物(邻,对'-滴滴伊)在库欣病长期治疗期间的血浆水平监测
Eur J Clin Pharmacol. 1991;41(3):259-61. doi: 10.1007/BF00315440.
6
The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.在正常甘油三酯血症和高甘油三酯血症患者中,邻对滴滴滴(米托坦)在血清脂蛋白中的分布情况。
Cancer Chemother Pharmacol. 1992;29(4):331-4. doi: 10.1007/BF00685956.
7
Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.米托坦[1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷;邻,对'-滴滴滴]及其对,对'-和间,对'-异构体的牛肾上腺皮质转化
Biochem Pharmacol. 1995 May 17;49(10):1483-9. doi: 10.1016/0006-2952(95)00028-x.
8
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.肾上腺皮质癌患者米托坦及其代谢物血浆水平的年周期变化。
J Pharm Pharmacol. 2017 Nov;69(11):1524-1530. doi: 10.1111/jphp.12798. Epub 2017 Aug 15.
9
o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
Eur J Clin Pharmacol. 1985;29(4):483-7. doi: 10.1007/BF00613466.
10
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.米托坦与乳糜微粒和血清脂蛋白的关联:对治疗肾上腺皮质癌的实际意义。
Eur J Endocrinol. 2016 Mar;174(3):343-53. doi: 10.1530/EJE-15-0946. Epub 2015 Dec 15.

引用本文的文献

1
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.米托坦的挑战性药代动力学:一种需要新包装的老药。
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21.
2
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.人群药代动力学和遗传药理学分析在肾上腺皮质癌患者中的米托坦:朝着个体化剂量迈进。
Clin Pharmacokinet. 2021 Jan;60(1):89-102. doi: 10.1007/s40262-020-00913-y.
3
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.

本文引用的文献

1
Studies of the pharmacology of o,p'DDD in man.人用邻对滴滴滴的药理学研究。
J Lab Clin Med. 1961 Aug;58:296-304.
2
[Regression under the influence of OP'DDD of a malignant cortico-adrenaloma and of its metastases (author's transl)].恶性肾上腺皮质瘤及其转移灶在邻对滴滴涕影响下的消退(作者译)
Nouv Presse Med. 1980 Jan 19;9(4):239-41.
3
Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.单次给药后及长期治疗期间,在不同溶媒中给予o,p'-滴滴滴后的血药浓度。
肾上腺皮质癌患者辅助使用米托坦治疗后,肾上腺功能不全经常恢复。
Cancers (Basel). 2020 Mar 10;12(3):639. doi: 10.3390/cancers12030639.
4
Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?米托坦在肾上腺皮质癌患者中的群体药代动力学建模与模拟:一种针对所有患者在三个月时达到目标的个体化给药方案?
Pharmaceutics. 2019 Oct 31;11(11):566. doi: 10.3390/pharmaceutics11110566.
5
PD-1 Blockade in Advanced Adrenocortical Carcinoma.PD-1 阻断剂治疗晚期肾上腺皮质癌。
J Clin Oncol. 2020 Jan 1;38(1):71-80. doi: 10.1200/JCO.19.01586. Epub 2019 Oct 23.
6
Current and emerging therapeutic options in adrenocortical cancer treatment.肾上腺皮质癌治疗的现有和新兴治疗选择。
J Oncol. 2012;2012:408131. doi: 10.1155/2012/408131. Epub 2012 Aug 14.
7
o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
Eur J Clin Pharmacol. 1985;29(4):483-7. doi: 10.1007/BF00613466.
8
Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.低剂量米托坦(邻,对'-滴滴滴)及其代谢物(邻,对'-滴滴伊)在库欣病长期治疗期间的血浆水平监测
Eur J Clin Pharmacol. 1991;41(3):259-61. doi: 10.1007/BF00315440.
9
The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.在正常甘油三酯血症和高甘油三酯血症患者中,邻对滴滴滴(米托坦)在血清脂蛋白中的分布情况。
Cancer Chemother Pharmacol. 1992;29(4):331-4. doi: 10.1007/BF00685956.
Cancer Chemother Pharmacol. 1981;7(1):51-4. doi: 10.1007/BF00258213.
4
Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients.
Am J Med. 1966 Oct;41(4):581-92. doi: 10.1016/0002-9343(66)90220-8.
5
Mitotane use in inoperable adrenal cortical carcinoma.米托坦在不可切除肾上腺皮质癌中的应用。
JAMA. 1973 Mar 5;223(10):1109-12.
6
Regression of an adrenal cortical carcinoma and its neovascular bed following mitotane therapy: a case report.米托坦治疗后肾上腺皮质癌及其新生血管床的消退:一例报告
Cancer. 1974 Dec;34(6):1882-7. doi: 10.1002/1097-0142(197412)34:6<1882::aid-cncr2820340605>3.0.co;2-q.
7
Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy.
Arch Intern Med. 1975 Sep;135(9):1257-8.
8
Estimation of o,p'-DDD in plasma by gas-liquid chromatography.
Clin Chim Acta. 1977 Apr 15;76(2):213-8. doi: 10.1016/0009-8981(77)90098-5.
9
o,p'--DDD and adrenal carcinoma.邻对滴滴滴与肾上腺皮质癌
Ir J Med Sci. 1978 Dec;147(12):437-40. doi: 10.1007/BF02939448.
10
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.o,p'-滴滴滴(米托坦)治疗肾上腺皮质癌:关于药物剂量、毒性及类固醇替代治疗的观察
Cancer. 1978 Nov;42(5):2177-81. doi: 10.1002/1097-0142(197811)42:5<2177::aid-cncr2820420514>3.0.co;2-x.